Novartis AG (NYSE:NVS) Shares Bought by Angeles Wealth Management LLC

Angeles Wealth Management LLC grew its holdings in shares of Novartis AG (NYSE:NVS) by 7.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,482 shares of the company’s stock after purchasing an additional 228 shares during the period. Angeles Wealth Management LLC’s holdings in Novartis were worth $352,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Frazier Financial Advisors LLC acquired a new stake in shares of Novartis in the 4th quarter worth approximately $26,000. Operose Advisors LLC acquired a new stake in Novartis during the 3rd quarter valued at $28,000. Planned Solutions Inc. acquired a new stake in Novartis during the 4th quarter valued at $31,000. AdvisorNet Financial Inc grew its holdings in Novartis by 480.0% during the 4th quarter. AdvisorNet Financial Inc now owns 348 shares of the company’s stock valued at $35,000 after buying an additional 288 shares during the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Novartis during the 3rd quarter valued at $39,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on NVS shares. BMO Capital Markets increased their target price on Novartis from $114.00 to $116.00 and gave the company a “market perform” rating in a report on Wednesday, April 24th. The Goldman Sachs Group assumed coverage on Novartis in a research note on Thursday, May 30th. They set a “buy” rating and a $120.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $116.67.

Novartis Trading Down 0.8 %

Shares of Novartis stock opened at $105.33 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.90 and a debt-to-equity ratio of 0.43. The firm has a market cap of $215.29 billion, a PE ratio of 14.21, a P/E/G ratio of 1.63 and a beta of 0.58. The business’s fifty day moving average is $98.84 and its two-hundred day moving average is $100.30. Novartis AG has a fifty-two week low of $92.19 and a fifty-two week high of $108.78.

Novartis (NYSE:NVS) last issued its earnings results on Tuesday, April 23rd. The company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.73 by $0.07. The business had revenue of $11.83 billion for the quarter, compared to analyst estimates of $11.50 billion. Novartis had a return on equity of 32.15% and a net margin of 31.33%. Analysts anticipate that Novartis AG will post 7.27 earnings per share for the current year.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.